Velocity Pharmaceutical Development
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Boulevard Ste 202, South San Francisco, ...Phone Number
(650) 745-8179Website
www.vpd.netRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Velocity Pharmaceutical Development
Velocity Pharmaceutical Development LLC (VPD) is dedicated to rapidly advancing promising drug candidates to clinical proof of concept using a highly virtual management model. VPD is staffed by a seasoned team of clinical drug developers with expertise identifying attractive drug candidates, target markets, and designing and managing outsourced clinical trials. This expert team manages multiple single asset companies to remove the costly overhead and misaligned incentives present in traditional biotechnology company structures. The company is located in South San Francisco, California.Explore more
Velocity Pharmaceutical Development Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Velocity Pharmaceutical Development your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check if Velocity Pharmaceutical Development has recently received funding, and reach out quickly before it becomes old news!
Velocity Pharmaceutical Development, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Velocity Pharmaceutical Development recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Velocity Pharmaceutical Development
Product Launch: Get notified when Velocity Pharmaceutical Development launches new products
Click to see if Velocity Pharmaceutical Development had a recent Job posting/layoffs
Check out if Velocity Pharmaceutical Development is spiking on competitors!
Funding: Get notified immidiatlly once Velocity Pharmaceutical Development has new funding data
Recommended Actions
Reach out to Masked Content who joined Velocity Pharmaceutical Development as Masked Content
Find more new buyers
Compare Similar Companies to Velocity Pharmaceutical Development
Compare insights from companies similar to Velocity Pharmaceutical Development, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Velocity Pharmaceutical Development is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Velocity Pharmaceutical Development is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Velocity Pharmaceutical Development.
Velocity Pharmaceutical Development Tech Stack
A closer look at the technologies used by Velocity Pharmaceutical Development
Velocity Pharmaceutical Development News & Media
Corsair Pharma Nets $23M Series B Financing
SUNNYVALE, CA, Corsair Pharma, a private biopharmaceutical company, announced the closing of its $23M Series B financing led by New Rhein Healthcare Investors.Altimmune Signs Definitive Agreement to Acquire Spitfire Pharma, Inc. Adding NASH Drug Candidate to Portfolio
GAITHERSBURG, Md., July 09, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has entered into an agreement to acquire Spitfire Pharma, Inc. (Spitfire) including its product candidate SP-1373 (to be renamed ALT-801), a potent GLP-1/Glucagon receptor co-agonist for the treatment of non-alcoholic steatohepatitis (NASH). The transaction is expected to close during July 2019, subject to customary closing conditions.Spitfire Pharma's SP-1373 outscored semaglutide and elafibranor in a biopsy-proven translational mouse model of non-alcoholic steatohepatitis (NASH)
SOUTH SAN FRANCISCO, Calif., Jan. 4, 2018 /PRNewswire/ -- Spitfire Pharma, Inc., ("Spitfire") announced today that SP-1373, its lead glucagon-like peptide-1 (GLP-1) and glucagon receptor dual agonist compound, demonstrated superior outcome measures in liver histopathology and metabolic...Corsair Pharma and United Therapeutics Enter into Strategic Collaboration to Advance Novel Treprostinil Prodrugs
SOUTH SAN FRANCISCO, Calif. and SILVER SPRING, Md., Jan. 3, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR), a leading biotechnology company focused on development of therapies for the treatment of pulmonary arterial hypertension (PAH), and Corsair Pharma, Inc., a priva...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Velocity Pharmaceutical Development
Sign Up For FreeTo access detailed company insights
Velocity Pharmaceutical Development LLC (VPD) is dedicated to rapidly advancing promising drug candidates to clinical proof of concept using a highly virtual management model. VPD is staffed by a seasoned team of clinical drug developers with expertise identifying attractive drug candidates, target markets, and designing and managing outsourced cli... Read More
